Amebiasis and Infection with Free-Living Amebae¶

Chapter 230 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Parasitic · Chapter 230

Key Clinical Points¶

90% of Entamoeba histolytica infections are asymptomatic cyst passage; only 10% progress to invasive amebiasis.
Entamoeba dispar is morphologically identical to E. histolytica but is non-pathogenic; differentiation requires serology or PCR.
Liver abscesses are the most common extraintestinal manifestation; rupture into the pericardium carries the gravest prognosis.
Metronidazole is the tissue amebicide of choice; luminal agents (iodoquinol, paromomycin) are required to eradicate cysts and prevent transmission.
Tinidazole is a longer-acting nitroimidazole effective for a single dose in some settings, with fewer adverse events than metronidazole.
Naegleria fowleri causes Primary Amebic Meningoencephalitis (PAM) via nasal irrigation or swimming in warm freshwater; mortality is nearly 100%.
Acanthamoeba and Balamuthia cause Granulomatous Amebic Encephalitis (GAE), typically in immunocompromised hosts; miltefosine is a key treatment.
Diagnosis of invasive amebiasis requires demonstration of hematophagous trophozoites in stool or positive serology.
Amebic liver abscess fluid is bacteriologically sterile and composed of necrotic debris; aspiration is indicated for pyogenic abscess differentiation.
Free-living amebae can survive in water systems and soil; prevention relies on sanitation and avoiding unpeeled produce in endemic areas.

1. DEFINITION & OVERVIEW¶

Amebiasis is an infection caused by Entamoeba histolytica, an intestinal protozoan.

Clinical Spectrum: • Asymptomatic Colonization: 90% of cases (cyst passage). • Invasive Amebiasis: 10% of cases; includes intestinal colitis (dysentery or diarrhea) or extraintestinal manifestations.

Key Definitions: • Ameboma: A mass lesion in the bowel lumen resulting from exuberant granulation tissue formation. • Environmental Enteropathy: Observed in tropical areas with endemic infections; associated with functional gastrointestinal impairment, malnutrition, and stunted growth in children.

1.1 Free-Living Amebae¶

Major human pathogens include Acanthamoeba, Naegleria, and Balamuthia.

Clinical Significance: • These parasites can cause fatal CNS infections. • Primary Amebic Meningoencephalitis (PAM): Caused by Naegleria fowleri. • Granulomatous Amebic Encephalitis (GAE): Caused by Acanthamoeba and Balamuthia.

2. EPIDEMIOLOGY¶

• General Prevalence: Common in underdeveloped tropical regions with poor sanitation; affects children <6 months. • Emerging Trends: Identified as a sexually transmitted disease among HIV-positive men who have sex with men (MSM) in Japan and Spain. • Global Impact: E. histolytica is the second most common cause of death from parasitic infection globally (after malaria). • Gender Disparity: Invasive colitis and liver abscesses are 10x more common in men than women. ◦ Mechanism: Differences in complement-mediated killing and testosterone effects on interferon γ secretion.

2.1 Free-Living Amebae Epidemiology¶

• Naegleria fowleri: Reported globally except Africa; most cases from warm, dry regions of the southwestern U.S. and Latin America. Since 2010, linked to piped water exposure. • Balamuthia mandrillaris: Clusters associated with organ transplantation since 2009. • Acanthamoeba: Outbreaks tied to contact lens use. • Distribution: Reported on all continents except Africa.

3. ETIOLOGY & PATHOPHYISIOLOGY¶

• Transmission: Ingestion of cysts from fecally contaminated sources (food-borne, oral-anal sexual practices, or rectal irrigation). • Pathogenesis and Pathology: ◦ Life Cycle Progression: Infection → Excystation in small intestine → Colonization of large bowel (90% asymptomatic) → Potential invasion of tissue/bloodstream → Extraintestinal complications (e.g., liver abscess). ◦ Molecular Mechanisms: • Attachment via Gal/GalNAc lectin. • Mucus degradation via glycosidases and proteases. • Tissue damage via contact-dependent (apoptosis, trogocytosis) and contact-independent (prostaglandin E2 release) mechanisms. ◦ Virulence Factors: Resistance to reactive oxygen species. • Modulating Factors: ◦ Gut Microbiome: Asymptomatic carriers have higher Ruminococcaceae abundance; symptomatic patients show reduced diversity. ◦ Genetics: Leptin receptor variants (Q223R) increase susceptibility to intestinal and liver disease. • Pharmacology: Metronidazole efficacy linked to inhibition of the thioredoxin–thioredoxin reductase system (protection against oxidative stress).

4. CLINICAL FEATURES¶

• Intestinal Manifestations: ◦ Asymptomatic: 90% of cases. ◦ Symptomatic Colitis: Develops 2–6 weeks post-exposure; presents with lower abdominal pain, diarrhea, and heme-positive stools. • Extraintestinal Manifestations (Liver Abscess): ◦ Presentation: Right upper quadrant pain, fever, and pleural effusion. ◦ Fever Only: Present in 10–15% of cases. ◦ Complications: Pleuropulmonary involvement (20–30%), hepatobronchial fistulas, and pericardial rupture (fatal). • CNS Infections: ◦ GAE (Acanthamoeba/Balamuthia): Occurs in immunocompromised patients; insidious onset. ◦ PAM (Naegleria fowleri): Fulminant; rapid progression to coma; 100% mortality rate.

4.1 Clinical Features of Free-Living Amebae¶

• Naegleria fowleri: Exposure via freshwater (91%) or tap water (nasal irrigation, backyard slides). • Acanthamoeba/Balamuthia: Found in soil and water systems; GAE presents with altered mental status, focal neurological deficits, and cutaneous ulcers in AIDS patients.

5. DIFFERENTIAL DIAGNOSIS¶

• Intestinal Amebiasis vs. Bacterial Diarrhea: ◦ Bacterial (Campylobacter, Shigella): Typically present with fever and neutrophils in stool. ◦ Amebic: Heme-positive stools with few neutrophils. • Amebic Liver Abscess vs. Pyogenic Abscess: ◦ Pyogenic features: Older age, history of bowel disease, positive serology. ◦ Amebic features: Younger age, no bowel disease history, negative serology. • Invasive Amebiasis General: ◦ Exclusionary finding: Absence of eosinophilia. ◦ Laboratory finding: Elevated alkaline phosphatase may be present. • CNS Infections vs. Bacterial Meningitis: ◦ Bacterial: Positive Gram stain. ◦ PAM: No bacteria on Gram stain; high WBC counts (up to 20,000/μL), elevated protein, and low glucose. ◦ Serology: Not useful for acute PAM; use PCR and histopathology.

5.1 Differential Diagnosis of Free-Living Amebae CNS Infections¶

• PAM vs. Bacterial Meningitis: Distinguished by absence of bacteria on CSF Gram stain. • GAE: Mimics space-occupying lesions with focal neurological deficits.

6. INVESTIGATIONS & DIAGNOSIS¶

Stool Examination: • Method: Hematoxylin-eosin or trichrome stains. • Procedure: Examine 3 fresh samples (trophozoites lyse rapidly).
Endoscopy: • Procedure: Sigmoidoscopy with biopsy. • Purpose: Confirm ameboma (caution in fulminant colitis).
Serology: • Method: ELISA.
Sensitivity: >90% for invasive disease.
Imaging & Aspiration (Liver Abscess):
Imaging: Identify location and size.
Aspiration: Differentiate from pyogenic abscess (pyogenic is typically not sterile).
CNS Infection Diagnosis:
CSF Wet Mount: Detect motile N. fowleri trophozoites.
PCR/Histopathology: Used for GAE diagnosis.

7. MANAGEMENT & TREATMENT¶

Tissue Amebic Treatment:
Metronidazole: 10–20 mg/kg PO tid for 5–10 days (or 750 mg PO or IV for 5–10 days).
Tinidazole: 2 g single dose.
Ornidazole: 2 g single dose.
Luminal Agents (Cyst Eradication):
Paromomycin: 30–40 mg/kg PO tid for 5–10 days (or 500 mg tid for 10 days).
Iodoquinol: 650 mg PO tid for 20 days.
Liver Abscess Management:
Percutaneous drainage: Indicated if abscess >5 cm or complicated.
Free-Living Amebae Treatment:
Miltefosine (GAE): 50 mg PO bid for 14 days; contraindicated in pregnancy.
Amphotericin B (PAM): 0.7–1.0 mg/kg IV qd; monitor renal function and electrolytes.
Fluconazole (Adjunctive GAE): 400 mg PO daily; contraindicated in pregnancy.

7.1 Drug Therapy for Amebiasis¶

• Metronidazole: 10–20 mg/kg PO tid × 5–10 days | Side effects: nausea, metallic taste; contraindicated in pregnancy. • Tinidazole: 2 g single dose | Fewer adverse events than metronidazole. • Ornidazole: 2 g single dose. • Paromomycin: 30–40 mg/kg PO tid × 5–10 days (or 500 mg tid for 10 days) | Lumen-specific; not absorbed systemically. • Iodoquinol: 650 mg PO tid × 20 days | Lumen-specific; may cause visual disturbances.

7.2 Treatment of Free-Living Amebae CNS Infections¶

• Miltefosine: 50 mg PO bid × 14 days (GAE) | Contraindicated in pregnancy. • Amphotericin B: 0.7–1.0 mg/kg IV qd (PAM) | Monitor renal function and electrolytes. • Fluconazole: 400 mg PO daily (adjunctive for GAE) | Contraindicated in pregnancy.

8. PROGNOSIS & COMPLICATIONS¶

• Asymptomatic Infections: Resolve spontaneously. • Invasive Amebiasis: 10% mortality rate if untreated. • Liver Abscess Complications: - Pericardial rupture: Fatal in >90% of cases. • PAM: Universally fatal within 1 week. • GAE: Variable prognosis; survival possible in immunocompetent patients with early miltefosine.

9. SPECIAL CONSIDERATIONS¶

• HIV-Positive Patients: Amebiasis may present atypically or be more severe. • Travelers: From endemic areas with fever of unknown origin should be tested for E. histolytica. • Organ Transplant Recipients: GAE is a rare but serious complication requiring prompt diagnosis.

10. KEY PEARLS & CLINICAL TRAPS¶

• Diagnostic Clues: Heme-positive stools with few neutrophils suggest amebiasis over bacterial diarrhea. • What Excludes the Diagnosis: - Presence of bacteria on CSF Gram stain excludes PAM. - Eosinophilia excludes invasive amebiasis.

Reference Tables¶

TABLE 230-1 Drug Therapy for Amebiasis INDICATION Asymptomatic carriage Acute colitis¶

Harrison's 22e, p.1757

INDICATION	THERAPY
Asymptomatic carriage	Luminal agent: iodoquinol (650-mg tablets), 650 mg tid for 20 days; or paromomycin (250-mg tablets), 500 mg tid for 10 days
Amebic liver abscess	Metronidazole, 750 mg PO or IV for 5–10 days; or tinidazole, 2 g PO once; or ornidazole,a 2 g PO once
	plus
	Luminal agent as above